Cardiology

The CARMELINA trial demonstrated noninferiority of linagliptin compared with placebo in CV events in high risk people with type 2 diabetes. 

Could older recommendations of maintaining a blood pressure of 140/90 mmHg be misleading in younger adults with type 1 diabetes for cardiovascular risk reduction? 

The results of EMPA-REG OUTCOME Trial assess the role of empagliflozin in patients with type 2 diabetes and atherosclerotic cardiovascular disease.

Myocardial flow reserve plays a significant role as a predictor of cardiac death in patients with diabetes.

The results of the STENO-2 study assessing the benefit of intensified therapy on risk of stroke.

Strong results motivate the ADA to update its Standard of Care for patients with diabetes.

Specific antihypertensive treatment goals in high-risk patients are a widely controversial topic; which type of patient with diabetes benefits most from blood pressure lowering medications?

Expansion of the original 2015 approval makes Praluent a strong lipid-lowering candidate for patients with diabetes and other cardiovascular concerns.

The face of heart disease is changing in the U.S., and obesity and diabetes may be key factors.

Is one more important than the other?